Scandion Oncology co-founders extend lock-up period
Scandion Oncology A/S (“Scandion Oncology”) announces that its two co-founders, CEO Nils Brünner and CSO Jan Stenvang, have extended the lock-up period for their Scandion Oncology shares with an additional three months (until October 1, 2020). In total, the lock-up agreements correspond to approximately 13 percent of the votes and capital in Scandion Oncology.
CEO Nils Brünner and CSO Jan Stenvang have signed and prolonged the lock-up agreements for their shares with three months. The two co-founders commit to retain 90 percent of their holdings in the company until October 1, 2020. The following parties have updated their lock-up agreements:
Nils Brünner 1.083.240*
* Privately and through the company TIMPCO NB ApS
Jan Stenvang 1.391.064
Nils Brünner, CEO of Scandion Oncology says:
“We have no intention to sell any Scandion Oncology shares now. We are looking forward to the near future where the first clinical data with SCO-101 in combination with chemotherapy in drug resistant colorectal cancer patients will be presented. We see Scandion Oncology as a growth company with strong potential to reach its goals and planned milestones.”
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on June 30, 2020.
Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology - the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company's leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: www.scandiononcology.com.
NextCell Pharma completes a directed share issue to a strategic partner
The Board of Directors of NextCell Pharma AB (”NextCell or the ”Company”) has today, based on the authorization granted by the Annual General Meeting held on 24 November 2020, resolved on a directed issue of 286 666 new shares (the “Share Issue”) to Polski Bank Komórek Macierzystych S.A (”PBKM”), Eu...
NextCell Pharma genomför riktad nyemission till en strategisk partner
Styrelsen i NextCell Pharma AB ("NextCell" eller ”Bolaget”) har idag, med stöd av bolagsstämmans bemyndigande den 24 november 2020, beslutat om en riktad nyemission av 286 666 aktier (”Nyemissionen”) till Polski Bank Komórek Macierzystych S.A (”PBKM”), Europas största stamcellbank och viktig samarbe...
Codonics orders 8 WasteLog systems
In December 2020, Codonics Inc, Middleburg Heights, Ohio, US and Pharmacolog entered into a long-term partnership agreement for the US market. Prior to that, in the autumn of 2020, the companies had collaborated to integrate the companies' products in order to create an efficient workflow when contr...
Codonics beställer 8 WasteLog system
Codonics Inc, Middleburg Heights, Ohio, US och Pharmacolog ingick i december 2020 ett långsiktigt partneravtal gällande den amerikanska marknaden. Bolagen hade dessförinnan under hösten 2020 samarbetat för att integrera bolagens produkter för att skapa ett effektivt arbetsflöde vid kontroll av retur...